Trial
NCT04777851
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Translational Research in Oncology
Collaborators
Bayer
Condition
Carcinoma, Hepatocellular
Intervention
Regorafenib in combination with pembrolizumab
Why stopped
The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve the target sample size within a reasonable timeframe. Consequently, a business decision has been made to discontinue funding for the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-09